Shortening clinical developments timeline using novel GPEx® Lightning technology for generating stable, high producing cell pools and cell lines
Speed and efficiency remain major drivers for developers bringing their protein-based biologics to first-in-human studies. For 20 years, GPEx® cell line development technology has provided a proven approach to generate high expressing, highly stable mammalian cell lines with 16 commercially approved biologics that have been developed to date. Building off the synergies of GPEx® technology, a glutamine-synthetase knockout, targeted gene insertion and two proprietary concepts, Catalent recently introduced GPEx Lightning, a fast, flexible way to shorten the path to production of cGMP product. During this talk, we share the latest data leveraging GPEx® Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx® suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.
- Latest updates to the GPEx® suite of technologies developed by Catalent
- Accelerated timeline by GPEx® Lightning to generate biotherapeutics for fist-in-human studies
Performance of GPEx® Lightning on generating stable cell pools and cell lines
